Harmony Biosciences Holdings Inc. has announced the ongoing regulatory review of their investigational drug BP1.15205, a highly potent orexin 2 receptor agonist, designed to treat narcolepsy and other central disorders of hypersomnolence. The company is in the process of completing an Investigational Medicinal Product Dossier (IMPD) application with the European Medicines Agency $(EMA)$ and plans to file an Investigational New Drug $(IND.AU)$ application with the U.S. Food and Drug Administration (FDA). A first-in-human study is slated to begin in the second half of 2025, with topline clinical data expected in 2026. These regulatory steps mark a significant advancement in Harmony Biosciences' commitment to expanding their sleep-wake franchise and potentially offering a novel treatment for individuals affected by hypersomnolence disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。